Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified vs standard docetaxel regimens in poorly chemotherapy-tolerant mCRPC
ChiCTR2000041337Phase 4Recruiting
- Sponsor
- Beijing Chaoyang Huanxing Cancer Hospital
- Start
- Jan 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of docetaxel in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Beijing Chaoyang Huanxing Cancer Hospital. Primary endpoints: Overall survival and Incidence of grade ≥3 adverse reactions. Started Jan 2020; status: recruiting.
02
Drugs
docetaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on ChiCTR2000041337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041337.